Jazz Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 1/6
Jazz Pharmaceuticals has a total shareholder equity of $3.8B and total debt of $5.7B, which brings its debt-to-equity ratio to 151.7%. Its total assets and total liabilities are $11.4B and $7.6B respectively. Jazz Pharmaceuticals's EBIT is $775.6M making its interest coverage ratio 2.9. It has cash and short-term investments of $2.0B.
Key information
151.7%
Debt to equity ratio
US$5.71b
Debt
| Interest coverage ratio | 2.9x |
| Cash | US$1.98b |
| Equity | US$3.76b |
| Total liabilities | US$7.60b |
| Total assets | US$11.36b |
Recent financial health updates
Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden
Jun 23
Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?
Feb 18Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly
Oct 31Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?
Jul 12We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt
Apr 12Recent updates
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 25Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst
Sep 19Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely
Jul 18Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden
Jun 23Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues
Jun 21Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off
Apr 15Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price
Apr 02Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?
Feb 18Updated View On Jazz Pharmaceuticals' 2025 Goals
Jan 29Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking
Dec 26Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly
Oct 31Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?
Jul 12We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt
Apr 12Jazz Pharmaceuticals: Monopoly In The Narcolepsy Drug Market
Aug 24Jazz begins phase 3 trial of cannabis drug Epidiolex for rare epilepsy
Aug 18Financial Position Analysis
Short Term Liabilities: JAZZ's short term assets ($3.7B) exceed its short term liabilities ($1.6B).
Long Term Liabilities: JAZZ's short term assets ($3.7B) do not cover its long term liabilities ($6.0B).
Debt to Equity History and Analysis
Debt Level: JAZZ's net debt to equity ratio (99%) is considered high.
Reducing Debt: JAZZ's debt to equity ratio has increased from 53.7% to 151.7% over the past 5 years.
Debt Coverage: JAZZ's debt is not well covered by operating cash flow (18.8%).
Interest Coverage: JAZZ's interest payments on its debt are not well covered by EBIT (2.9x coverage).